Skip to content

A Path to Coverage. Built One Case at a Time.

Industries - Technology

PRO-spectus helps digital therapeutic manufacturers build the evidence, the process, and the payer record that turn early access into lasting coverage.

 

Prepared for Each Payer.                                  Informed by Every Decision.

FDA authorization is the start of the coverage journey. We help you prepare before the first submission, with complete clinical documentation, anticipated payer questions, and a clear review and appeal plan.

Each outcome informs the next case, building your evidence base with every patient, appeal, and payer decision.

 

A balanced approach to access and coverage.

We align near-term patient support with long-term coverage strategy. Bridge and assistance programs have a defined role that accounts for their financial impact.

Alongside that support, we submit eligible cases, pursue appeals where supported, and document outcomes to help early access build toward lasting coverage.

A model designed for how digital therapeutics reach patients.

Digital therapeutics are evaluated, prescribed, accessed, and reimbursed differently from traditional products. Your access model should reflect that. Our support programs are inherently flexible, from a single workstream to a full program.

Patient Access, Built Around Every Patient and Every Case

Is coverage and reimbursement possible for digital therapeutics?

Yes. Coverage and reimbursement for digital therapeutics are achievable, and PRO-spectus has experience building the path. Each payor evaluates products on its own terms, so the process is built one case at a time.

What happens after a digital therapeutic receives FDA authorization?

Authorization marks the start of the coverage journey rather than the end. We help you plan that journey before your first submission, so your product reaches patients with the reimbursement foundation it needs.

How does PRO-spectus help build coverage for a digital therapeutic?

Our teams prepare each case with complete clinical documentation and anticipate each payor’s questions. We map the review and appeal path in advance, and capture every outcome so it informs the next case.

Should we provide free product while coverage is being built?

Bridge and assistance programs can support patients in the near term, and they carry real financial weight. We help you use them with purpose and a clear plan, paired with a deliberate coverage process.

Does PRO-spectus support early-stage digital therapeutics companies?

Yes. We work with companies at different stages and scale our support to fit. You can start with a focused workstream and expand as your product and market grow.